These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38334611)

  • 21. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
    Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
    Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Ezh2 In Vitro and the Decline of
    Hong F; Zhao M; Zhang L; Feng L
    Stem Cells Dev; 2019 May; 28(10):649-658. PubMed ID: 30887911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
    Lu VM; Daniels DJ
    Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.
    Krug B; De Jay N; Harutyunyan AS; Deshmukh S; Marchione DM; Guilhamon P; Bertrand KC; Mikael LG; McConechy MK; Chen CCL; Khazaei S; Koncar RF; Agnihotri S; Faury D; Ellezam B; Weil AG; Ursini-Siegel J; De Carvalho DD; Dirks PB; Lewis PW; Salomoni P; Lupien M; Arrowsmith C; Lasko PF; Garcia BA; Kleinman CL; Jabado N; Mack SC
    Cancer Cell; 2019 May; 35(5):782-797.e8. PubMed ID: 31085178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
    Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing.
    Rosiak-Stec K; Grot D; Rieske P
    PLoS One; 2020; 15(9):e0239325. PubMed ID: 32946483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.
    Cui D; Sajan P; Shi J; Shen Y; Wang K; Deng X; Zhou L; Hu P; Gao L
    Oncotarget; 2017 Apr; 8(15):25345-25361. PubMed ID: 28445981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
    Chan KM; Fang D; Gan H; Hashizume R; Yu C; Schroeder M; Gupta N; Mueller S; James CD; Jenkins R; Sarkaria J; Zhang Z
    Genes Dev; 2013 May; 27(9):985-90. PubMed ID: 23603901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
    Day CA; Hinchcliffe EH; Robinson JP
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
    Bunse L; Rupp AK; Poschke I; Bunse T; Lindner K; Wick A; Blobner J; Misch M; Tabatabai G; Glas M; Schnell O; Gempt J; Denk M; Reifenberger G; Bendszus M; Wuchter P; Steinbach JP; Wick W; Platten M
    Neurol Res Pract; 2022 May; 4(1):20. PubMed ID: 35599302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
    Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
    Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.